New Drug Application (NDA) submission on track for January 2026NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: ...

AXS-12's clinical development program in narcolepsy includes three controlled efficacy trials, and a completed long-term safety trial. The drug has already been granted orphan drug designation, a ...

Axsome Therapeutics (AXSM) on Wednesday said it received formal pre–New Drug Application (NDA) meeting minutes from the U.S.

The biopharmaceutical company accepted for filing a supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation, and has granted the application priority review designation, ...

The latest update is out from Axsome Therapeutics ( (AXSM) ).

Narcolepsy is a neurological disorder that affects your sleep-wake cycle. We still don’t know what causes the condition. But most people with type 1 narcolepsy -- the kind with sudden muscle weakness, ...

Amanda Myers is a senior at the University of Florida majoring in pre-veterinary studies. She is also a competitive weightlifter, and a speaker for Project Sleep's Rising Voices of Narcolepsy program.

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

Narcolepsy is a rare condition that will make someone fall asleep abruptly — even in the middle of the day during an activity. It's possible to treat narcolepsy and manage your symptoms with lifestyle ...

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. Matthew Horsnell began ...

Taylor Leamey wrote about all things wellness for CNET, specializing in mental health, sleep and nutrition coverage. She has invested hundreds of hours into studying and researching sleep and holds a ...